OMEROS CORP Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- OMEROS CORP stock issued during period, value, new issues for the quarter ending 2025-06-30 was $6.29M.
- OMEROS CORP stock issued during period, value, new issues for the quarter ending 2020-09-30 was $93.67M.
- OMEROS CORP stock issued during period, value, new issues for fiscal 2020 was $93.67M, a 72.71% increase from fiscal 2019.
- OMEROS CORP stock issued during period, value, new issues for fiscal 2019 was $54.24M.
- OMEROS CORP stock issued during period, value, new issues for fiscal 2017 was $63.66M, a 70.60% increase from fiscal 2016.
- OMEROS CORP stock issued during period, value, new issues for fiscal 2016 was $37.31M, a 52.81% decline from fiscal 2015.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2025-06-30 | $6.29M 10-Q · filed 2025-08-14 | |
| 2020-12-31 | $93.67M 10-K · filed 2023-03-13 | |
| 2020-09-30 | $93.67M 10-Q · filed 2021-11-09 | |
| 2019-12-31 | $54.24M 10-K · filed 2022-03-01 | |
| 2017-12-31 | $63.66M 10-K · filed 2020-03-02 | |
| 2016-12-31 | $37.31M 10-K · filed 2019-03-01 | |
| 2015-12-31 | $79.08M 10-K · filed 2018-03-01 | |
| 2014-12-31 | $37.75M 10-K · filed 2017-03-16 | |
| 2013-12-31 | $16.12M 10-K · filed 2016-03-15 | |
| 2012-12-31 | $32.31M 10-K · filed 2015-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |